In a study involving 30 patients with type 2 diabetes mellitus, intravenous administration of alpha-lipoic acid (ALA) for 3 weeks was found to reduce concentrations of asymmetric dimethylarginine (mean change: -0.05 micromol/L) – which when elevated, is associated with cardiovascular events in patients with type 2 diabetes. No such change was found when placebo was administered (0.01 micromol/L). ALA results did not affect levels of symmetric dimethylarginine and L-arginine. The authors conclude, "Long-term studies need to demonstrate if ALA may cause cardiovascular risk reduction."

What Is Remote Patient Monitoring? How It’s Transforming Modern Healthcare
At Dr. Christopher Calapai’s office, we want to make medical care as simple and convenient for you as possible. One